Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
AVADEL CNS PHARMACEUTICALS, LLC v. BECERRA et al
Case Number:
1:22-cv-02159
Court:
Nature of Suit:
Administrative Procedure Act/Review or Appeal of Agency Decision
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
November 04, 2022
Feds Escape Suit Over Delayed Narcolepsy Drug
A Washington, D.C., federal judge has allowed the U.S. government to exit drugmaker Avadel's suit over the halted approval of narcolepsy medication Lumryz, finding that there are other avenues of relief available, such as related patent litigation that triggered the stay.
-
July 22, 2022
Drugmaker Says FDA Delayed OK Of Narcolepsy Medication
A drug developer is suing the U.S. Department of Health and Human Services over its yearlong delay in approving a newer and allegedly more efficient narcolepsy drug amid a fight over whether the drug would infringe one of the patents that protects Jazz Pharmaceuticals' billion-dollar grip on selling medications treating the condition.